Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Ho

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Human Pathology|April 5, 2019
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangementSnjezana Dogan, Charlotte K Y Ng, Bin Xu, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Endocrine-Related Cancer|April 23, 2021
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancersKathleen A Luckett, Jennifer R Cracchiolo, Gnana P Krishnamoorthy, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
The New England Journal of Medicine|February 15, 2013
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerAlan L Ho, Ravinder K Grewal, Rebecca Leboeuf, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Thyroid : Official Journal of the American Thyroid Association|June 12, 2025
Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid CancerJustin Choi, Eric Sherman, Edward Christopher Dee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell CarcinomaDan P Zandberg, Jacob B Allred, Ari J Rosenberg, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Human Pathology|April 5, 2019
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangementSnjezana Dogan, Charlotte K Y Ng, Bin Xu, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Endocrine-Related Cancer|April 23, 2021
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancersKathleen A Luckett, Jennifer R Cracchiolo, Gnana P Krishnamoorthy, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
The New England Journal of Medicine|February 15, 2013
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerAlan L Ho, Ravinder K Grewal, Rebecca Leboeuf, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Thyroid : Official Journal of the American Thyroid Association|June 12, 2025
Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid CancerJustin Choi, Eric Sherman, Edward Christopher Dee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell CarcinomaDan P Zandberg, Jacob B Allred, Ari J Rosenberg, et al.
Pageof 12